Daiichi Sankyo Europe

Daiichi Sankyo Europe is the European headquarters of the global pharmaceutical leader Daiichi Sankyo, based in Munich, Germany. The company is dedicated to the development and commercialization of innovative therapies, with a primary focus on oncology and cardiovascular diseases. Its research is anchored by its proprietary DXd antibody-drug conjugate (ADC) technology, which has produced transformative treatments such as Enhertu for HER2-positive cancers. Beyond oncology, the company maintains a robust cardiovascular portfolio, including the oral anticoagulant Lixiana and the cholesterol-lowering agent Nilemdo. Daiichi Sankyo Europe operates across more than 20 countries and maintains a significant manufacturing facility in Pfaffenhofen, Germany.